ENTO
Entero Therapeutics
ENTO
ENTO
7 hedge funds and large institutions have $168K invested in Entero Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
Holders
7
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$120K | |
| 2 | +$17.7K | |
| 3 | +$12.6K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3K |
Top Sellers
| 1 | -$18K | |
| 2 | -$17K | |
| 3 | -$15K | |
| 4 |
Goldman Sachs
New York
|
-$6K |
| 5 |
Citigroup
New York
|
-$3K |